Hospitals | April 04, 2026
Kauvery Hospital sets new benchmark in high-risk cardiac care
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
Subscribe To Our Newsletter & Stay Updated
